CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.384
EU - Europa 2.954
AS - Asia 1.348
SA - Sud America 18
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
AN - Antartide 1
Totale 7.726
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.370
CN - Cina 1.018
GB - Regno Unito 945
SE - Svezia 424
IT - Italia 421
IE - Irlanda 367
FR - Francia 311
DE - Germania 207
SG - Singapore 136
FI - Finlandia 123
KR - Corea 45
UA - Ucraina 42
VN - Vietnam 38
PL - Polonia 25
HK - Hong Kong 21
JP - Giappone 21
BE - Belgio 20
NL - Olanda 17
IN - India 15
IR - Iran 13
CZ - Repubblica Ceca 12
RU - Federazione Russa 11
CA - Canada 10
TR - Turchia 7
CL - Cile 6
AZ - Azerbaigian 5
CH - Svizzera 5
EU - Europa 5
AU - Australia 4
EG - Egitto 4
ES - Italia 4
KG - Kirghizistan 4
MA - Marocco 4
PE - Perù 4
PH - Filippine 4
RO - Romania 4
UZ - Uzbekistan 4
AM - Armenia 3
AT - Austria 3
CO - Colombia 3
ID - Indonesia 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
CR - Costa Rica 2
DK - Danimarca 2
EC - Ecuador 2
LY - Libia 2
MX - Messico 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BG - Bulgaria 1
BO - Bolivia 1
BR - Brasile 1
GR - Grecia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
TN - Tunisia 1
Totale 7.726
Salva come PNG Salva come JPEG
Città #
Southend 901
Chandler 819
Dublin 367
Woodbridge 297
Ashburn 261
Beijing 256
Jacksonville 195
Ann Arbor 181
Verona 127
Lawrence 125
Princeton 125
Wilmington 114
New York 104
Jinan 101
Singapore 90
Houston 73
Sindelfingen 64
Redmond 59
Shenyang 58
Nanjing 54
Tianjin 53
Hebei 50
Seoul 45
Helsinki 43
Seattle 37
Washington 32
Kent 31
Nanchang 31
Haikou 29
Hangzhou 27
Milan 26
Changsha 25
Ningbo 25
Zhengzhou 25
Boardman 24
Dong Ket 22
Brussels 20
Taizhou 20
Guangzhou 19
Falls Church 18
Taiyuan 18
Tokyo 18
Jiaxing 17
Los Angeles 17
Redwood City 16
Hong Kong 15
Norwalk 13
Bologna 12
Brno 12
Augusta 11
Fuzhou 11
Lanzhou 11
Rome 11
San Francisco 10
Lancaster 9
Munich 9
Trento 9
San Mateo 8
Toronto 8
Este 7
Lappeenranta 7
Padova 7
Amsterdam 6
Chicago 6
Dearborn 6
Dongguan 6
Ardabil 5
Bussolengo 5
Clearwater 5
Fairfield 5
Isola della Scala 5
Kochi 5
Menlo Park 5
Paris 5
Baku 4
Bishkek 4
Boydton 4
Brugnera 4
Cagliari 4
Cambridge 4
Council Bluffs 4
Falkenstein 4
Fremont 4
Lima 4
Lozzo Atestino 4
Monmouth Junction 4
Tashkent 4
Zanjan 4
Andover 3
Cairate 3
Detroit 3
Duncan 3
Düsseldorf 3
Frankfurt am Main 3
Kebon Manggis 3
London 3
Messina 3
Moscow 3
Neiva 3
Riva 3
Totale 5.385
Salva come PNG Salva come JPEG
Nome #
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 142
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 130
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 117
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 115
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 113
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 107
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 102
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 99
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 97
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 96
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 95
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 95
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 95
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 91
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 89
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 87
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 85
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 84
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 83
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 82
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 82
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 82
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 80
Clinical meta-analyses of targeted therapies in adenocarcinoma. 77
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 74
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 74
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 73
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 71
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 71
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 70
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 69
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 69
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 68
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 68
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 67
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 67
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 67
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 65
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 64
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 63
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 63
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 62
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 60
Do immune checkpoint inhibitors need new studies methodology? 60
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 60
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 59
Muscle derangement and alteration of the nutritional machinery in NSCLC 59
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 59
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 59
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 58
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 58
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 58
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 58
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 57
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 56
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 56
Physical activity and exercise in lung cancer care: will promises be fulfilled? 56
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 56
Sorafenib for lung cancer: is the "Battle" still open ? 55
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 55
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 55
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 55
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 54
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 52
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 52
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 52
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 52
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. 51
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 51
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 51
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 49
Cellular and molecular biology of small cell lung cancer: an overview 49
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 49
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. 49
Exercise levels and preferences in cancer patients: a cross-sectional study 49
mTOR Cross-Talk in Cancer and Potential for Combination Therapy. 48
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 47
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 46
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 46
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 46
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 46
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 46
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 45
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 45
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 45
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 44
Exercise oncology: It is time to make a change 44
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 43
A multimodal approach to cancer-related cachexia: from theory to practice 43
Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening 42
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 41
Melanoma: oncogenic drivers and the immune system 40
Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. 40
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 40
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 40
Exercise and anemia in cancer patients: could make the difference? 40
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 39
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 38
Physical Activity for Oncological Patients in COVID-19 Era: No Time to Relax 38
Neoplasie a sede primitiva ignota (Capitolo 18) 37
Totale 6.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.826
article - articoli 32.998
book - libri 0
conference - conferenze 485
curatela - curatele 0
other - altro 151
patent - brevetti 0
selected - selezionate 0
volume - volumi 192
Totale 67.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020664 92 17 15 28 91 51 85 35 52 63 51 84
2020/2021815 92 127 35 112 99 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/202554 54 0 0 0 0 0 0 0 0 0 0 0
Totale 7.995